Patent · US Active

Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

US8481039B2 · kind B2 · utility

1Cited by

4References

19Claims

0Family size

Assignee

KYOWA HAKKO KIRIN CO., LTD. · JP

Inventors

Eisuke Mekada · Suita, JP
Ryo Iwamoto · Suita, JP
Shingo Miyamoto · Tokyo, JP
Kenya Shitara · Tokyo, JP
Akiko Furuya · Tokyo, JP
Kazuyasu Nakamura · Machida, JP
Kumiko Takahashi · Cambridge, US
Hiroshi Ando · Ozu, JP
Kazuhiro Masuda · Oshima, JP
Yuka Sasaki · Machida, JP

Key dates

Filing date	Feb 3, 2012
Grant date	Jul 9, 2013
Priority date	—
Expiry date	Feb 3, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.